The purpose of this study is to evaluate the effectiveness of elacytarabine, an investigational drug, for the treatment of acute myeloid leukemia (AML) that has stopped responding to or has progressed despite two or three prior regimens of chemotherapy. Patients will be randomly assigned to receive elacytarabine or a standard therapy (investigator’s choice), but not both. <//p>
Elacytarabine is a new medicine that has put some patients with late-stage AML into remission. It induces cancer cell death by interfering with the cell’s DNA.